ReviewRespiratory research2005
Serum biomarkers in interstitial lung diseases.
Review in Respiratory research, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00989846 (Feasibility Study on Establishing Biomarkers in Lung Diseases), which is not on this map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Feasibility Study on Establishing Biomarkers in Lung Diseases
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Serum Krebs von den Lungen-6 level predicts disease progression in interstitial lung disease.PloS one · 2020Trial
- The value of serum biomarkers in the management of interstitial lung disease in patients with connective tissue disease: a protocol for an observational study.Journal of thoracic disease · 2026Article
- Article
- The exosomal protein biomarkers auxiliary in diagnosis of interstitial lung disease.Respiratory research · 2025Article
- A Case of Interstitial Pneumonia Leading to Respiratory Failure Several Months After COVID-19 Infection.Cureus · 2025Article
- High Interleukin-13 level is associated with disease stability in interstitial Lung disease.Heliyon · 2024Article
- Biomarkers in idiopathic pulmonary fibrosis: Current insight and future direction.Chinese medical journal pulmonary and critical care medicine · 2024Article
- The effectiveness and pharmacoeconomic study of using different corticosteroids in the treatment of hypersensitivity pneumonitis.BMC pulmonary medicine · 2024Article
- Oscillometry in Lung Function Assessment: A Comprehensive Review of Current Insights and Challenges.Cureus · 2023Review
- Article
- Diagnosis of Fibrotic Hypersensitivity Pneumonitis: Is There a Role for Biomarkers?Life (Basel, Switzerland) · 2023Review
- Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis.Arthritis & rheumatology (Hoboken, N.J.) · 2022Article
- Blood KL-6 predicts prognosis in primary Sjögren's syndrome-associated interstitial lung disease.Scientific reports · 2022Article
- Changes in blood Krebs von den Lungen-6 predict the mortality of patients with acute exacerbation of interstitial lung disease.Scientific reports · 2022Article
- In hospital risk factors for acute kidney injury and its burden in patients with Sars-Cov-2 infection: a longitudinal multinational study.Scientific reports · 2022Article
- The Prognostic Value of Krebs von den Lungen-6 and Surfactant Protein-A Levels in the Patients with Interstitial Lung Disease.Journal of translational internal medicine · 2021Article
- Neutrophil-To-Lymphocyte Ratio and Systemic Immune-Inflammation Index-Biomarkers in Interstitial Lung Disease.Medicina (Kaunas, Lithuania) · 2020Article
- Patients with Interstitial Lung Disease Secondary to Autoimmune Diseases: How to Recognize Them?Diagnostics (Basel, Switzerland) · 2020Review
- Clinical and Diagnostic Significance of Lactate Dehydrogenase and Its Isoenzymes in Animals.Veterinary medicine international · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of biomarkers in medicine lies in their ability to detect disease and support diagnostic and therapeutic decisions. New research and novel understanding of the molecular basis of the disease reveals an abundance of exciting new biomarkers who present a promise for use in the everyday clinical practice. The past fifteen years have seen the emergence of numerous clinical applications of several new molecules as biologic markers in the research field relevant to interstitial lung diseases (translational research). The scope of this review is to summarize the current state of knowledge about serum biomarkers in interstitial lung diseases and their potential value as prognostic and diagnostic tools and present some of the future perspectives and challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.